EMAIL THIS PAGE TO A FRIEND

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.


PMID 24362713

Abstract

Checkpoint kinase (Chk) inhibitors are thought to increase the cytotoxic effects of DNA-damaging agents and are undergoing clinical trials. The present study was aimed to assess the potential to use the Chk1 and Chk2 inhibitor, AZD7762, with other anticancer agents in chemotherapy to treat ovarian clear cell carcinoma. Four ovarian clear cell carcinoma cell lines were used in this study. We treated the cells with AZD7762 and anticancer agents, then assessed cell viability, cell cycle distribution, apoptosis, and the expression of protein in apoptotic pathways and molecules downstream of the Chk signaling pathways. We also investigated the effects of these drug combinations on tumor growth in a nude mouse xenograft model. Synergistic effects from the combination of AZD7762 and cisplatin were observed in all 4 cell lines. However, we observed additive effects when AZD7762 was combined with paclitaxel on all cell lines tested. AZD7762 effectively suppressed the Chk signaling pathways activated by cisplatin, dramatically enhanced expression of phosphorylated H2A.X, cleaved caspase 9 and PARP, decreased the proportion of cells in the gap 0/ gap 1 phase and the synthesis-phase fraction, and increased apoptotic cells. Combinations of small interfering RNA against Chk 1 and small interfering RNA against Chk2 enhanced the cytotoxic effect of cisplatin in both RMG-I and KK cells. Finally, treating mice-bearing RMG-I with AZD7762 and cisplatin significantly suppressed growth of tumors in a xenograft model. The present study indicates that chemotherapy with AZD7762 and cisplatin should be explored as a treatment modality for women with ovarian clear cell carcinoma.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA001473
Anti-CASP9 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4503332
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
SAB4503333
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
SAB4503334
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
SAB4503335
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
C7729 Anti-Caspase 9 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4300683
Anti-Caspase 9 antibody produced in rabbit, affinity isolated antibody
SAB3500405
Anti-Caspase-9 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA001878
Anti-CHEK2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
AV30290
Anti-CHEK2 antibody produced in rabbit, affinity isolated antibody
SAB2100415
Anti-CHEK2 antibody produced in rabbit, affinity isolated antibody
SAB3500192
Anti-Chk2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4300514
Anti-H2AFX (Ab-139) antibody produced in rabbit, affinity isolated antibody
SAB4500487
Anti-PARP (Cleaved-Asp214) antibody produced in rabbit, affinity isolated antibody
SAB4500488
Anti-PARP (Cleaved-Gly215) antibody produced in rabbit, affinity isolated antibody
P7605 Anti-PARP antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
AV33754
Anti-PARP1 antibody produced in rabbit, IgG fraction of antiserum
HPA045168
Anti-PARP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
PLA0294
Goat anti-H2AX Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.
61506
L-Threonine, certified reference material, TraceCERT®
C4H9NO3
PHR1242
L-Threonine, Pharmaceutical Secondary Standard; Certified Reference Material
C4H9NO3
T1340000
L-Threonine, European Pharmacopoeia (EP) Reference Standard
C4H9NO3
WH0001111M5
Monoclonal Anti-CHEK1 antibody produced in mouse, clone 2G3, purified immunoglobulin, buffered aqueous solution
SAB5300524 Monoclonal Anti-CHEK1 antibody produced in mouse, clone 2G1D5, ascites fluid
C9358
Monoclonal Anti-Chk1 antibody produced in mouse, ~2 mg/mL, clone DCS-310, purified immunoglobulin, buffered aqueous solution
WH0003014M5
Monoclonal Anti-H2AFX antibody produced in mouse, clone 3F4, purified immunoglobulin, buffered aqueous solution
SAB1403902 Monoclonal Anti-H2AFX, (N-terminal) antibody produced in mouse, clone 2H5, purified immunoglobulin, buffered aqueous solution
Y0000698
Paclitaxel, European Pharmacopoeia (EP) Reference Standard
C47H51NO14
Y0000700
Paclitaxel natural for peak identification, European Pharmacopoeia (EP) Reference Standard
C47H51NO14
Y0000719
Paclitaxel semi-synthetic for peak identification, European Pharmacopoeia (EP) Reference Standard
C47H51NO14